Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

56.12 -0.13 (-0.23%)
Streaming Delayed Price Updated: 10:34 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox ↗
 
Via Benzinga
News headline image
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March ↗
Via The Motley Fool
Topics Bankruptcy Economy World Trade
News headline image
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today ↗
Via The Motley Fool
Topics Government World Trade
News headline image
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies. 
Via Investor's Business Daily
News headline image
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why ↗
Via The Motley Fool
News headline image
Market Whales and Their Recent Bets on CRSP Options ↗
 
Via Benzinga
News headline image
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
2 Beaten-Down Stocks to Buy on the Dip ↗
Via The Motley Fool
News headline image
2 No-Brainer Biotech Stocks to Buy Right Now ↗
Via The Motley Fool
News headline image
Cathie Wood Stands By Tesla's $2,600 Price Target Despite 40% Stock Drop: 'It's Winner Take Most ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Continues To Load Up On Tempus AI, Dumps Bitcoin-Focused Block In Tech Meltdown Aftermath ↗
On Tuesday, Cathie Wood‘s Ark Invest executed notable trades, including significant activity involving Tempus AI Inc. (NASDAQ:TEM), Block Inc. (NYSE:XYZ), and DraftKings Inc.< 
Via Benzinga
Topics Artificial Intelligence
News headline image
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. ↗
Via The Motley Fool
News headline image
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street ↗
Via The Motley Fool
News headline image
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
News headline image
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
This Informatica Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
The Ultimate Healthcare Stock to Buy With $500 Right Now ↗
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday ↗
Via The Motley Fool
News headline image
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. ↗
The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers. 
Via Investor's Business Daily
News headline image
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move ↗
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? ↗
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox ↗
Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV. 
Via Benzinga
News headline image
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy. 
Via MarketBeat
News headline image
My Top 5 Stocks to Buy in Early 2025 ↗
Via The Motley Fool
News headline image
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases ↗
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end. 
Via Benzinga
News headline image
3 Unstoppable Stocks to Buy in 2025 ↗
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia ↗
Ark Invest made significant trades involving Tempus AI, CRISPR Therapeutics, UiPath, Roblox, Reddit, Accolade, and Ibotta. ARKG and ARKK funds bought shares, while ARKW and ARKF funds sold shares. 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.